AstraZeneca: promising results in lung cancer

(CercleFinance.com) - On Tuesday AstraZeneca and its Japanese partner Daiichi Sankyo reported encouraging results for their investigational drug Datopotamab Deruxtecan in advanced non-small cell lung cancer.


According to interim results from a phase 1b study, the antibody-conjugate produced an overall response rate of 37% in participants also receiving Merck's immunotherapy Keytruda, a level deemed "promising" by both partners.

The findings were unveiled at a late-breaking presentation at the annual meeting of the International Association for the Study of Lung Cancer (IASLC).


Copyright (c) 2022 CercleFinance.com. All rights reserved.